224 related articles for article (PubMed ID: 37249632)
21. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy.
Stauder MC; Caudle AS; Allen PK; Shaitelman SF; Smith BD; Hoffman KE; Buchholz TA; Chavez-Macgregor M; Hunt KK; Meric-Bernstam F; Woodward WA
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):637-44. PubMed ID: 27681760
[TBL] [Abstract][Full Text] [Related]
22. Optimizing Axillary Management in Clinical T1-2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes.
Kantor O; Means J; Grossmith S; Dey T; Bellon JR; Mittendorf EA; King TA
Ann Surg Oncol; 2022 Feb; 29(2):972-980. PubMed ID: 34467507
[TBL] [Abstract][Full Text] [Related]
23. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
Tinterri C; Canavese G; Gatzemeier W; Barbieri E; Bottini A; Sagona A; Caraceni G; Testori A; Di Maria Grimaldi S; Dani C; Boni L; Bruzzi P; Fernandes B; Scorsetti M; Zambelli A; Gentile D;
Br J Surg; 2023 Aug; 110(9):1143-1152. PubMed ID: 37471574
[TBL] [Abstract][Full Text] [Related]
24. Stage migration in breast cancer: surgical decisions concerning isolated tumour cells and micro-metastases in the sentinel lymph node.
de Widt-Levert L; Tjan-Heijnen V; Bult P; Ruers T; Wobbes T
Eur J Surg Oncol; 2003 Apr; 29(3):216-20. PubMed ID: 12657229
[TBL] [Abstract][Full Text] [Related]
25. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU
Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659
[TBL] [Abstract][Full Text] [Related]
26. A multi-dimensional nomogram to predict non-sentinel lymph node metastases in T1-2HR+ breast cancer.
Xiang K; Chen J; Min Y; Chen H; Yang J; Hu D; Han Y; Yin G; Feng Y
Front Endocrinol (Lausanne); 2023; 14():1121394. PubMed ID: 37476497
[TBL] [Abstract][Full Text] [Related]
27. Role of number of sentinel nodes in predicting non-sentinel node metastasis in breast cancer.
Dong LF; Xu SY; Long JP; Wan F; Chen YD
J Int Med Res; 2018 Feb; 46(2):828-835. PubMed ID: 29441833
[TBL] [Abstract][Full Text] [Related]
28. Locoregional Management of the Axilla in Mastectomy Patients with One or Two Positive Sentinel Nodes: The Role of Intraoperative Pathology.
Davis J; Boughey JC; Hoskin TL; Day CN; Cheville JC; Piltin MA; Hieken TJ
Clin Breast Cancer; 2021 Oct; 21(5):458-465. PubMed ID: 33839043
[TBL] [Abstract][Full Text] [Related]
29. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
Giuliano AE; Hunt KK; Ballman KV; Beitsch PD; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; McCall LM; Morrow M
JAMA; 2011 Feb; 305(6):569-75. PubMed ID: 21304082
[TBL] [Abstract][Full Text] [Related]
30. Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes.
Weiss A; Lin H; Babiera GV; Bedrosian I; Shaitelman SF; Shen Y; Kuerer HM; Mittendorf EA; Caudle AS; Hunt KK; Hwang RF
Breast Cancer Res Treat; 2019 Jul; 176(2):435-444. PubMed ID: 31025270
[TBL] [Abstract][Full Text] [Related]
31. Independent risk factors for axillary lymph node metastasis in breast cancer patients with one or two positive sentinel lymph nodes.
Zhang W; Xu J; Wang K; Tang XJ; Liang H; He JJ
BMC Womens Health; 2020 Jul; 20(1):143. PubMed ID: 32646416
[TBL] [Abstract][Full Text] [Related]
32. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
[TBL] [Abstract][Full Text] [Related]
33. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
[TBL] [Abstract][Full Text] [Related]
34. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach.
Damin AP; Zancan M; Melo MP; Biazus JV
Breast Cancer Res Treat; 2021 Apr; 186(2):527-534. PubMed ID: 33165710
[TBL] [Abstract][Full Text] [Related]
35. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
[TBL] [Abstract][Full Text] [Related]
36. Routine completion axillary lymph node dissection for positive sentinel nodes in patients undergoing mastectomy is not associated with improved local control.
Crawford JD; Ansteth M; Barnett J; Glissmeyer M; Johnson NG
Am J Surg; 2013 May; 205(5):581-4; discussion 584. PubMed ID: 23592166
[TBL] [Abstract][Full Text] [Related]
37. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
[TBL] [Abstract][Full Text] [Related]
38. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
Krag DN; Anderson SJ; Julian TB; Brown AM; Harlow SP; Costantino JP; Ashikaga T; Weaver DL; Mamounas EP; Jalovec LM; Frazier TG; Noyes RD; Robidoux A; Scarth HM; Wolmark N
Lancet Oncol; 2010 Oct; 11(10):927-33. PubMed ID: 20863759
[TBL] [Abstract][Full Text] [Related]
39. Extranodal Tumor Deposits in the Axillary Fat Indicate the Need for Axillary Dissection Among T1-T2cN0 Patients with Positive Sentinel Nodes.
Mamtani A; Barrio AV; Goldman DA; Wen HY; Vincent A; Morrow M
Ann Surg Oncol; 2020 Oct; 27(10):3585-3592. PubMed ID: 32488512
[TBL] [Abstract][Full Text] [Related]
40. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
